Fig. 1

Clinical developments during three years of anti-TNF therapy. Mean (95 % CI) developments in visual analog scale (VAS) global, VAS pain, EuroQ ol 5-Dimensions (EQ-5D) utility, Evaluator’s global assessment of disease activity, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in the non-radiographic axial spondyloarthritis and ankylosing spondylitis groups over time, using last observation carried forward imputed data